SLS SELLAS Life Sciences Group, Inc. - Common Stock
Sobre SELLAS Life Sciences Group, Inc. - Common Stock Visão geral da empresa da Wikipedia
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
Ler mais
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
SLS Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
SLS Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
SLS Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
- Compra forte 1 16,7%
- Compra 4 66,7%
- Manter 1 16,7%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
2 analistas · 2026-08-14Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 31 de Março de 2026 | $-0.05 | $-0.04 | -0.01% |
| 31 de Dezembro de 2025 | $-0.05 | $-0.07 | 0.02% |
| 30 de Setembro de 2025 | $-0.06 | $-0.07 | 0.01% |
| 30 de Junho de 2025 | $-0.07 | $-0.08 | 0.01% |
| 31 de Março de 2025 | $-0.07 | $-0.11 | 0.04% |
| 31 de Dezembro de 2024 | $-0.08 | $-0.11 | 0.03% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
Balanço Patrimonial 22
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
Fluxo de Caixa 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
Eficiência 1
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
Taxas de Crescimento 1
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
Avaliação (TTM) 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
Demonstração de Resultados 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
Balanço Patrimonial 15
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
Fluxo de Caixa 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
Eficiência 1
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Avaliação (TTM) 9
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | — | — | $0 | $1M | $8M |
| Margem Operacional % | — | — | — | -4195.0% | -332.8% |
| Lucro líquido | $-27M | $-31M | $-37M | $-41M | $-21M |
| EPS Diluído | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| Índice de Liquidez Seca | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 231 declarantes · $1.2B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 87 (+24 vs trimestre anterior) | 19 (+4 vs trimestre anterior) | 70 (+12 vs trimestre anterior) | 38 (+15 vs trimestre anterior) | +39.9M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| STATE STREET CORP | $191.829.196 | 12.996.558 | 15,97% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $121.417.310 | 8.226.105 | 10,11% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105.640.272 | 7.157.200 | 8,79% | Opção de compra |
| Anson Funds Management LP | $66.420.000 | 4.500.000 | 5,53% | Ações |
| CITADEL ADVISORS LLC | $64.157.292 | 4.346.700 | 5,34% | Opção de compra |
| GEODE CAPITAL MANAGEMENT, LLC | $61.905.400 | 4.193.009 | 5,15% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61.832.592 | 4.189.200 | 5,15% | Opção de venda |
| CITADEL ADVISORS LLC | $33.333.984 | 2.258.400 | 2,77% | Opção de venda |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31.897.821 | 2.161.099 | 2,66% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30.266.812 | 2.050.597 | 2,52% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $28.553.511 | 2.304.561 | 2,38% | Ações |
| VANGUARD GROUP INC | $27.868.421 | 7.392.154 | 2,32% | Ações |
| Anson Funds Management LP | $27.245.484 | 1.845.900 | 2,27% | Opção de venda |
| PERCEPTIVE ADVISORS LLC | $22.140.000 | 1.500.000 | 1,84% | Opção de venda |
| VANGUARD FIDUCIARY TRUST CO | $19.707.050 | 1.335.166 | 1,64% | Ações |
| Sio Capital Management, LLC | $18.165.132 | 1.230.700 | 1,51% | Opção de venda |
| BNP PARIBAS FINANCIAL MARKETS | $15.823.045 | 1.072.022 | 1,32% | Ações |
| MILLENNIUM MANAGEMENT LLC | $13.372.560 | 906.000 | 1,11% | Opção de venda |
| BARCLAYS PLC | $11.831.616 | 801.600 | 0,98% | Opção de venda |
| Anson Funds Management LP | $11.808.000 | 800.000 | 0,98% | Opção de compra |
| BNP PARIBAS FINANCIAL MARKETS | $11.734.200 | 7.950 | 0,98% | Opção de venda |
| JANE STREET GROUP, LLC | $11.058.192 | 749.200 | 0,92% | Opção de compra |
| MORGAN STANLEY | $9.922.380 | 672.248 | 0,83% | Ações |
| BANK OF AMERICA CORP /DE/ | $9.150.359 | 619.943 | 0,76% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8.339.518 | 565.008 | 0,69% | Ações |
| JANE STREET GROUP, LLC | $7.462.700 | 505.603 | 0,62% | Ações |
| Balyasny Asset Management L.P. | $7.380.000 | 500.000 | 0,61% | Opção de venda |
| LMR Partners LLP | $6.642.000 | 450.000 | 0,55% | Opção de venda |
| NOMURA HOLDINGS INC | $6.273.000 | 425.000 | 0,52% | Opção de compra |
| DIADEMA PARTNERS LP | $5.904.000 | 400.000 | 0,49% | Opção de compra |
| Swiss National Bank | $5.319.504 | 360.400 | 0,44% | Ações |
| XTX Topco Ltd | $5.300.168 | 359.090 | 0,44% | Ações |
| Ikarian Capital, LLC | $5.235.372 | 354.700 | 0,44% | Opção de venda |
| CITIGROUP INC | $4.659.717 | 315.699 | 0,39% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $4.580.973 | 310.364 | 0,38% | Ações |
| DAGCO, INC. | $4.351.740 | 1.028.780 | 0,36% | Ações |
| Everhart Financial Group, Inc. | $4.251.146 | 288.018 | 0,35% | Ações |
| Rafferty Asset Management, LLC | $3.540.806 | 239.892 | 0,29% | Ações |
| RHUMBLINE ADVISERS | $3.400.726 | 230.402 | 0,28% | Ações |
| Walleye Capital LLC | $3.377.088 | 228.800 | 0,28% | Opção de venda |
| GOLDMAN SACHS GROUP INC | $3.125.991 | 211.788 | 0,26% | Ações |
| TUDOR INVESTMENT CORP ET AL | $3.087.792 | 209.200 | 0,26% | Opção de venda |
| WELLINGTON MANAGEMENT GROUP LLP | $2.992.738 | 202.760 | 0,25% | Ações |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.982.996 | 202.100 | 0,25% | Opção de venda |
| Jefferies Financial Group Inc. | $2.958.775 | 200.459 | 0,25% | Ações |
| Jefferies Financial Group Inc. | $2.953.476 | 200.100 | 0,25% | Opção de venda |
| Mariner, LLC | $2.925.609 | 198.212 | 0,24% | Ações |
| MILLENNIUM MANAGEMENT LLC | $2.895.912 | 196.200 | 0,24% | Opção de compra |
| Bank of New York Mellon Corp | $2.801.212 | 189.784 | 0,23% | Ações |
| ALPS ADVISORS INC | $2.776.459 | 188.107 | 0,23% | Ações |
| JANE STREET GROUP, LLC | $2.405.880 | 163.000 | 0,20% | Opção de venda |
| LPL Financial LLC | $2.297.586 | 155.663 | 0,19% | Ações |
| SIMPLEX TRADING, LLC | $2.274.501 | 154.099 | 0,19% | Ações |
| BlackRock, Inc. | $2.222.708 | 150.590 | 0,19% | Ações |
| WELLS FARGO & COMPANY/MN | $2.208.775 | 149.646 | 0,18% | Ações |
| Vontobel Holding Ltd. | $2.166.207 | 146.762 | 0,18% | Ações |
| TUDOR INVESTMENT CORP ET AL | $2.069.352 | 140.200 | 0,17% | Opção de compra |
| Vanguard Global Advisers, LLC | $1.918.874 | 130.005 | 0,16% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.859.598 | 125.989 | 0,15% | Ações |
| Caption Management, LLC | $1.845.000 | 125.000 | 0,15% | Opção de venda |
| PROFUND ADVISORS LLC | $1.780.159 | 120.607 | 0,15% | Ações |
| MetLife Investment Management, LLC | $1.624.810 | 110.082 | 0,14% | Ações |
| Daiwa Securities Group Inc. | $1.589.652 | 107.700 | 0,13% | Opção de venda |
| Daiwa Securities Group Inc. | $1.512.900 | 102.500 | 0,13% | Ações |
| DIADEMA PARTNERS LP | $1.476.000 | 100.000 | 0,12% | Opção de venda |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1.467.144 | 99.400 | 0,12% | Ações |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.405.300 | 95.210 | 0,12% | Ações |
| Harvest Investment Services, LLC | $1.394.554 | 94.482 | 0,12% | Ações |
| ORBIMED ADVISORS LLC | $1.365.300 | 92.500 | 0,11% | Opção de venda |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1.229.582 | 83.305 | 0,10% | Ações |
| Invesco Ltd. | $1.104.816 | 74.852 | 0,09% | Ações |
| Gotham Asset Management, LLC | $1.097.317 | 74.344 | 0,09% | Ações |
| FULCRUM WEALTH ADVISORS, LLC | $1.081.214 | 73.253 | 0,09% | Ações |
| ALLIANCEBERNSTEIN L.P. | $998.534 | 236.060 | 0,08% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $978.588 | 66.300 | 0,08% | Ações |
| Verition Fund Management LLC | $916.596 | 62.100 | 0,08% | Opção de venda |
| OSAIC HOLDINGS, INC. | $889.776 | 60.284 | 0,07% | Ações |
| FIFTH THIRD BANCORP | $888.404 | 60.190 | 0,07% | Ações |
| State of New Jersey Common Pension Fund D | $857.069 | 58.067 | 0,07% | Ações |
| Verition Fund Management LLC | $832.464 | 56.400 | 0,07% | Opção de compra |
| Police & Firemen's Retirement System of New Jersey | $821.630 | 55.666 | 0,07% | Ações |
| ARIZONA STATE RETIREMENT SYSTEM | $731.388 | 49.552 | 0,06% | Ações |
| Caption Management, LLC | $728.745 | 49.373 | 0,06% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722.310 | 48.937 | 0,06% | Ações |
| Russell Investments Group, Ltd. | $704.494 | 47.730 | 0,06% | Ações |
| SIG BROKERAGE, LP | $689.292 | 46.700 | 0,06% | Opção de compra |
| Vanguard Investments Australia, Ltd. | $684.643 | 46.385 | 0,06% | Ações |
| COMMONWEALTH EQUITY SERVICES, LLC | $665.481 | 45.087 | 0,06% | Ações |
| INSTRUMENTAL WEALTH, LLC | $662.931 | 44.914 | 0,06% | Ações |
| Persistent Asset Partners Ltd | $655.647 | 758 | 0,05% | Opção de compra |
| Virtus Investment Advisers, LLC | $616.791 | 41.788 | 0,05% | Ações |
| Accurate Wealth Management, LLC | $614.707 | 47.462 | 0,05% | Ações |
| AXXCESS WEALTH MANAGEMENT, LLC | $610.665 | 41.373 | 0,05% | Ações |
| KLP KAPITALFORVALTNING AS | $600.732 | 40.700 | 0,05% | Ações |
| SJS Investment Consulting Inc. | $590.400 | 40.000 | 0,05% | Ações |
| Wealthfront Advisers LLC | $587.773 | 39.822 | 0,05% | Ações |
| Quantinno Capital Management LP | $546.651 | 37.036 | 0,05% | Ações |
| Visionary Horizons, LLC | $531.360 | 36.000 | 0,04% | Ações |
| Kestra Advisory Services, LLC | $516.305 | 34.980 | 0,04% | Ações |
| NORTHSTAR ASSET MANAGEMENT Co | $509.400 | 45.000 | 0,04% | Ações |
Executivos da empresa 42 insiders · 17 diretores · 9 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16 de Junho de 2026 A | 1.759.183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15 de Março de 2011 A | 92.994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 7 de Janeiro de 2026 A | 554.327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20 de Abril de 2018 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13 de Abril de 2011 A | 379.294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15 de Janeiro de 2009 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 7 de Janeiro de 2026 A | 557.805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22 de Janeiro de 2024 A | 40.918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22 de Janeiro de 2024 A | 117.225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14 de Março de 2019 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13 de Março de 2018 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15 de Março de 2011 A | 14.065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15 de Março de 2011 A | 41.083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | 15 de Março de 2011 A | 60.559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | 15 de Março de 2011 A | 44.940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15 de Abril de 2010 A | 5.750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31 de Março de 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | Conselheiro | 7 de Janeiro de 2026 A | 154.400 | 1 | 0 | $100.806 |
| John Varian | Conselheiro | 7 de Janeiro de 2026 A | 72.900 | 0 | 0 | $0 |
| Jane Wasman | Conselheiro | 7 de Janeiro de 2026 A | 92.900 | 0 | 0 | $0 |
| David A Scheinberg | Conselheiro | 7 de Janeiro de 2026 A | 73.082 | 0 | 0 | $0 |
| Robert L Van Nostrand | Conselheiro | 7 de Janeiro de 2026 A | 82.900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | Conselheiro | 14 de Março de 2019 A | — | 0 | 0 | $0 |
| Fabio Lopez | Conselheiro | 12 de Junho de 2018 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | 10 de Outubro de 2017 A | 34.690 | 0 | 0 | $0 |
| William Ashton | — | 10 de Outubro de 2017 A | 38.154 | 0 | 0 | $0 |
| Richard Chin | — | 10 de Outubro de 2017 A | 31.339 | 0 | 0 | $0 |
| Rudolph Nisi | — | 10 de Outubro de 2017 A | 42.918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | 10 de Outubro de 2017 A | 56.950 | 0 | 0 | $0 |
| Mary Ann Gray | — | 10 de Outubro de 2017 A | 39.167 | 0 | 0 | $0 |
| Stephen S Galliker | — | 10 de Outubro de 2017 A | 36.039 | 0 | 0 | $0 |
| Thomas J Knapp | — | 6 de Fevereiro de 2017 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | 17 de Janeiro de 2017 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | 1 de Junho de 2016 M | 18.702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | 18 de Dezembro de 2015 A | 415.972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | 19 de Junho de 2015 A | 5.000 | 0 | 0 | $0 |
| Margaret Kivinski | — | 16 de Janeiro de 2015 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | 30 de Junho de 2014 J | 2.461 | 0 | 0 | $0 |
| Mark J Ahn | — | 30 de Junho de 2014 A | 116.225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | 29 de Janeiro de 2013 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | 29 de Dezembro de 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | 15 de Janeiro de 2009 A | — | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 2 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 declarações | 10 de Outubro de 2018 | — | Declaração inicial | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 8 de Janeiro de 2018 | — | Declaração inicial | M&A / venda | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 29 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,77% | 288.499 SH | 8 de Agosto de 2026 | Diário |
| IWC · iShares Trust | 0,50% | 640.415 SH | 8 de Agosto de 2026 | Diário |
| LABU · Direxion Shares ETF Trust | 0,26% | 268.465 NS | 30 de Abril de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,23% | 316.525 SH | 8 de Agosto de 2026 | Diário |
| ICOP · iShares Trust | 0,22% | 126.361 SH | 8 de Agosto de 2026 | Diário |
| CANC · Tema ETF Trust | 0,22% | 40.702 NS | 31 de Maio de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,16% | 202.339 SH | 8 de Agosto de 2026 | Diário |
| IWO · iShares Trust | 0,14% | 1.712.069 SH | 8 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,08% | 1.086.285 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,07% | 4.828.431 SH | 8 de Agosto de 2026 | Diário |
| ISCG · iShares Trust | 0,07% | 57.511 SH | 8 de Agosto de 2026 | Diário |
| GSSC · Goldman Sachs ETF Trust | 0,05% | 51.293 NS | 31 de Maio de 2026 | N-PORT |
| PICK · iShares, Inc. | 0,04% | 122.564 SH | 8 de Agosto de 2026 | Diário |
| ITWO · ProShares Trust | 0,04% | 8.088 NS | 31 de Maio de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,04% | 540.244 SH | 8 de Agosto de 2026 | Diário |
| ISCF · iShares Trust | 0,04% | 30.200 SH | 8 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | 0,03% | 8.283 SH | 8 de Agosto de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.134.285 SH | 8 de Agosto de 2026 | Diário |
| WSML · iShares Trust | 0,03% | 16.889 SH | 8 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,03% | 74.459 NS | 30 de Abril de 2026 | N-PORT |
| UWM · ProShares Trust | 0,02% | 6.326 NS | 31 de Maio de 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 6.397 NS | 31 de Maio de 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 161 NS | 31 de Maio de 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 64.480 NS | 31 de Maio de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3.554 NS | 31 de Maio de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 273.812 SH | 8 de Agosto de 2026 | Diário |
| IWV · iShares Trust | 0,00% | 43.929 SH | 8 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.908.560 SH | 8 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 15.706 SH | 8 de Agosto de 2026 | Diário |